Results 111 to 120 of about 6,510 (202)

Unexplained RV Lead Failure Manifesting as Atonic Seizures [PDF]

, 2023
Kooima, Blake, et. al.
core   +2 more sources

Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency. [PDF]

J Hum Immun
Gilbert KM, Aglan M, Jogdand A, Khairnar NV, Ssemaganda H, Ong MS, Farmer JR.   +6 more
europepmc   +1 more source

Popul Health Manag [PDF]

Oral antivirals for COVID-19 can be game changers in low- and middle-income countries (LMICs). Challenges that may hinder current and future oral antiviral rollouts span use in special populations, drug-drug and herb-drug interactions, adverse events ...

core  

Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study. [PDF]

Front Cell Infect Microbiol
Zhang Y, Yang X, Sun L, Zhang R, Fan W, Lin N, Lin B.   +6 more
europepmc   +1 more source

Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID diabetes risk among an older adult cohort: a target trial emulation study. [PDF]

BMC Med
Guo Z, Wei Y, Yang A, Wong CKH, Xiong X, Wang K, Lin G, Wang H, Hung CT, Li C, Yam CHK, Chow TY, Zhao S, Mok CKP, Hui DSC, Yeoh EK, Chong KC.   +16 more
europepmc   +1 more source

Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation. [PDF]

J Am Heart Assoc
Wong CK, So BY, Leung IS, Choo A, Chiu HAC, Tam FC, Lin M, Kwok WC, Lam SC, Chan KE, Un KC, Lam TH, Chu WM, Tam AR, Hung FN, Lip GYH, Tse HF.   +16 more
europepmc   +1 more source

Pharmacist follow-up of patients prescribed nirmatrelvir/ritonavir: a single-center retrospective analysis. [PDF]

J Pharm Health Care Sci
Shigeno A, Ohashi Y, Masui R, Kiryu A, Nagashima K, Ohashi H, Seto K, Masuda J, Teruya K, Ujiie M, Ohmagari N, Nishimura T.   +11 more
europepmc   +1 more source

Viral kinetics in adults with Covid-19 treated with nirmatrelvir-ritonavir or molnupiravir: a population-based, observational cohort study. [PDF]

Virol J
Prager M, Ensle D, Eser H, Glötzl F, Riedl B, Szell M, Valipour A, Zoufaly A, Wenisch C, Haider D, Burgmann H, Thalhammer F, Götzinger F, Jilma B, Karnthaler U, Zeitlinger M, Jorda A.   +16 more
europepmc   +1 more source

Association of Nirmatrelvir-ritonavir with intubation or mortality risks in severe COVID-19 patients: a comparative study. [PDF]

BMC Infect Dis
Luo W, Li KY, Zhu W, Dai C, Lin J, Lu F, Chen Q, Wang W, Zhuang Q, Lin Y.   +9 more
europepmc   +1 more source

Evolving role of novel COVID-19 Medicine Delivery Units [PDF]

, 2022
Goodman, Anna, Packham, Alice, Spence, Niamh   +2 more
core